Efficacy of Piriformis Block Using Intravenous Steroids with Bupivacaine versus Botox in Piriformis Syndrome
Article Sidebar
Main Article Content
Abstract
Background: Piriformis syndrome, a condition that affects predominantly females, leads to significant morbidity and impacts the quality of life. Despite its prevalence, it remains underdiagnosed, especially in the developed world. Treatment options include physiotherapy, painkillers, massage, heat, corticosteroids, local anesthetics, and botulinum toxin. However, comparative analysis of combination therapy versus botulinum toxin alone is limited.
Objective: To compare the efficacy of intravenous steroids combined with bupivacaine versus botulinum toxin (Botox) injections in the treatment of piriformis syndrome.
Methods: This quasi-experimental study was conducted at the Department of Anesthesiology, Combined Military Hospital, from January 2022 to December 2022, following ethical approval. The study included 100 patients diagnosed with piriformis syndrome, divided into two groups: Group L (n=50) received 10 ml of 0.25% bupivacaine with 40 mg of methylprednisolone, and Group B (n=50) received 100 U of botulinum toxin type A diluted in 10 ml distilled water. Standard monitoring was applied, and injections were performed under ultrasound guidance with the patients in the prone position. Pain scores were assessed using the Visual Analog Scale (VAS) at 24 hours, 72 hours, 7 days, and 28 days post-procedure. Patient satisfaction was measured using a 5-point Likert scale at 28 days. Data were analyzed using t-tests and chi-square tests, with significance set at p<0.05.
Results: The mean age was 36 ± 3.35 years in Group L and 35.82 ± 3.42 years in Group B (p=0.297). The mean weight was 75.82 ± 5.23 kg in Group L and 77.64 ± 4.47 kg in Group B (p=0.066). Before the procedure, both groups had a median VAS pain score of 7.0. At 24 hours, the median pain score was 4.0 in Group L and 5.0 in Group B (p=0.292). At 72 hours, Group L had a median pain score of 3.0 compared to 4.0 in Group B (p=0.010). At 7 days, the scores were 2.0 and 3.0 respectively (p=0.013), and at 28 days, they were 2.0 and 3.0 respectively (p=0.013). The median satisfaction score at 28 days was 1.0 in Group L and 2.0 in Group B (p=0.043).
Conclusion: Combination therapy with local anesthetics and steroids is superior to botulinum toxin in reducing pain and improving patient satisfaction in piriformis syndrome. This approach should be considered the first-choice treatment.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Siahaan YMT, Tiffani P, Tanasia A. Ultrasound-Guided Measurement of Piriformis Muscle Thickness to Diagnose Piriformis Syndrome. Front Neurol. 2021;12:721966.
Siahaan YMT, Ketaren RJ, Hartoyo V, Tiffani P. The Predisposing Factors of Piriformis Syndrome: Study in a Referral Hospital. MNJ Malang Neurol J. 2019;5(2):76-9.
Probst D, Stout A, Hunt D. Piriformis Syndrome: A Narrative Review of the Anatomy, Diagnosis, and Treatment. PM&R. 2019;11:S54-S63.
Shahzad M, Rafique N, Shakil-ur-Rehman S, Ali Hussain S. Effects of ELDOA and Post-Facilitation Stretching Technique on Pain and Functional Performance in Patients with Piriformis Syndrome: A Randomized Controlled Trial. J Back Musculoskelet Rehabil. 2020;33(6):983-8.
Zhang W, Luo F, Sun H, Ding H. Ultrasound Appears to Be a Reliable Technique for the Diagnosis of Piriformis Syndrome. Muscle Nerve. 2019;59(4):411-6.
Shah SS, Consuegra JM, Subhawong TK, Urakov TM, Manzano GR. Epidemiology and Etiology of Secondary Piriformis Syndrome: A Single-Institution Retrospective Study. J Clin Neurosci. 2019;59:209-12.
Sharma S, Kaur H, Verma N, Adhya B. Looking Beyond Piriformis Syndrome: Is It Really the Piriformis? Hip Pelvis. 2023;35(1):1.
Hlis R, Yan K, Xi Y, Chhabra A. Piriformis Syndrome: Muscle Thickness or Volume Does Not Correlate with Response to CT-Guided Injection. Skeletal Radiol. 2022:1-8.
Pande A, Gopinath R, Ali S, Adithyan R, Pandian S, Ghosh S. Piriformis Syndrome and Variants—A Comprehensive Review on Diagnosis and Treatment. J Spinal Surg. 2021;8(4):7-.
Vij N, Kiernan H, Bisht R, Singleton I, Cornett EM, Kaye AD, et al. Surgical and Non-Surgical Treatment Options for Piriformis Syndrome: A Literature Review. Anesth Pain Med. 2021;11(1).
Poutoglidou F, Piagkou M, Totlis T, Tzika M, Natsis K. Sciatic Nerve Variants and the Piriformis Muscle: A Systematic Review and Meta-Analysis. Cureus. 2020;12(11).
Shafshak TS, Elnemr R. The Visual Analogue Scale Versus Numerical Rating Scale in Measuring Pain Severity and Predicting Disability in Low Back Pain. J Clin Rheumatol. 2021;27(7):282-5.
Pimentel JL, Pimentel J. Some Biases in Likert Scaling Usage and Its Correction. Int J Sci Basic Appl Res. 2019;45(1):183-91.
Adiyatma H, Kurniawan SN. Piriformis Syndrome. J Pain Headache Vertigo. 2022;3(1):23-8.
Ahmed MAA. Dexamethasone Magnesium Sulfate as an Adjuvant to Local Anesthetics in the Ultra-Sound Guided Injection of Piriformis Muscle for the Treatment of Piriformis Syndrome. Open Anesth J. 2020;14(1).
Misirlioglu TO, Akgun K, Palamar D, Erden MG, Erbilir T. Piriformis Syndrome: Comparison of the Effectiveness of Local Anesthetic and Corticosteroid Injections: A Double-Blinded, Randomized Controlled Study. Pain Physician. 2015;18(2):163.
Fishman LM, Anderson C, Rosner B. BOTOX and Physical Therapy in the Treatment of Piriformis Syndrome. Am J Phys Med Rehabil. 2002;81(12):936-42.
Jankovic D, Peng P, André van Zundert M. Brief Review: Piriformis Syndrome: Etiology, Diagnosis, and Management. Can J Anaesth. 2013;60(10):1003.
Mitra SR, Roy S, Dutta AS, Ghosh A, Roy R, Jha AK. Piriformis Syndrome: A Review. J Evol Med Dent Sci. 2014;3(14):3804-15.
Sharma S, Kaur H, Verma N, Adhya B. Looking beyond Piriformis Syndrome: Is It Really the Piriformis?. Hip & Pelvis. 2023 Mar;35(1):1.